Update on hepatobiliary flukes: Fascioliasis, opisthorchiasis and clonorchiasis

Current Opinion in Infectious Diseases

Volumn 21, Issue 5, 2008, Pages 523-530

  Marcos, Luis A ^a,b   Terashima, Angelica ^a   Gotuzzo, Eduardo ^a,c  

^a INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^b UNIVERSITY OF TEXAS   (United States)

^c Hospital Nacional   (Peru)

Author keywords

Biliary tract; Flukes; Liver

Indexed keywords

PRAZIQUANTEL; TRICLABENDAZOLE;

BILE DUCT CARCINOMA; CHOLANGITIS; CHOLECYSTITIS; CHOLELITHIASIS; CLONORCHIASIS; CLONORCHIS SINENSIS; COMPUTER ASSISTED TOMOGRAPHY; EARLY DIAGNOSIS; FASCIOLA HEPATICA; FASCIOLIASIS; GEOGRAPHIC PATHOLOGY; HUMAN; INFECTION RISK; LIVER FIBROSIS; LIVER TUMOR; NONHUMAN; OPISTHORCHIASIS; OPISTHORCHIS VIVERRINI; PANCREATITIS; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; TREMATODIASIS; ANIMAL; ECHINOSTOMIASIS; HEPATOBILIARY SYSTEM; PARASITOLOGY; PATHOLOGY; TREMATODE;

ANIMALS; BILIARY TRACT; CLONORCHIASIS; ECHINOSTOMIASIS; FASCIOLIASIS; HUMANS; OPISTHORCHIASIS; TREMATODA; TREMATODE INFECTIONS;

EID: 55249124743     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32830f9818     Document Type: Review

References (67)

1. Keiser J, Utzinger J. Emerging foodborne trematodiasis. Emerg Infect Dis 2005; 11:1507-1514.
2. Marcos LA, Terashima A. Update on human fascioliasis in Peru: diagnosis, treatment and clinical classification proposal. Neotrop Helminthol 2007; 1:85-103. This study provides a good overview of the current state of knowledge in F. hepatica in Peru in the last decade on the basis of 1800 human cases.
3. Marcos LA, Tagle M, Terashima A, et al. Natural history, clinico-radiologic correlates and response to triclabendazole in acute massive fascioliasis. Am J Trop Med Hyg 2008; 78:222-227. There are few reviews of acute fascioliasis correlating clinical picture, diagnosis, CT findings and treatment response.
4. Marcos LA, Maco V, Samalvides F, et al. Risk factors for Fasciola hepatica infection in children: a case-control study. Trans R Soc Trop Med Hyg 2006; 100:158-166.
5. Marcos LA, Yi P, Machicado A, et al. Hepatic fibrosis and Fasciola hepatica infection in cattle. J Helminthol 2007; 81:381-386. This study associated the chronic infection, worm burden and the development of liver fibrosis in cattle infected by fascioliasis.
6. Keiser J, Engels D, Buscher G, Utzinger J. Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Investig Drugs 2005; 14:1513-1526.
7. Kaewpitoon N, Kaewpitoon SJ, Pengsaa P. Opisthorchiasis in Thailand: review and current status. World J Gastroenterol 2008; 14:2297-2302. Good review in the current state of knowledge on opistorchiasis in Thailand since 1950.
8. Sayasone S, Odermatt P, Phoumindr N, et al. Epidemiology of Opisthorchis viverrini in a rural district of southern Lao PDR. Trans R Soc Trop Med Hyg 2007; 101:40-47. This study provides information regarding the epidemiology of Opisthorchis in an endemic area.
9. Sriamporn S, Pisani P, Pipitgool V, et al. Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, Northeast Thailand. Trop Med Int Health 2004; 9:588-594.
10. Sripa B, Kaewkes S, Sithithaworn P, et al. Liver fluke induces cholangiocarcinoma. PLoS Med 2007; 4:201. Good review and nice description of liver flukes and cholangiocarcinoma in Asia. It described the pathogenesis from infection to cancer.
11. Tselepatiotis E, Mantadakis S, Papoulis E, et al. A case of Opisthorchis felineus infestation in a pilot from Greece. Infection 2003; 6:430-432.
12. Rim HJ. Clonorchiasis: an update. J Helminthol 2005; 79:269-281.
13. Lun ZR, Gasser RB, Lai DH, et al. Clonorchiasis: a key foodborne zoonosis in China. Lancet Infect Dis 2005; 5:31-41.
14. Liao WC, Wang HP, Chiu HM, et al. Multiple hepatic nodules: rare manifestation of clonorchiasis. J Gastroenterol Hepatol 2006; 21:1497-1500.
15. Park DH, Son HY. Clonorchis sinensis, images in clinical medicine. N Engl J Med 2008; 358:16.
16. Stunell H, Buckley O, Geoghegan T, Torreggiani WC. Recurrent pyogenic cholangitis due to chronic infestation with Clonorchis sinensis. Eur Radiol 2006; 16:2612-2614.
17. Choi D, Lim JH, Lee KT, et al. Cholangiocarcinoma and Clonorchis sinensis infection: a case-control study in Korea. J Hepatol 2006; 44:1066-1073.
18. Mas-Coma S, Bargues MD, Valero MA. Fascioliasis and other plant-borne trematode zoonoses. Int J Parasitol 2005; 35:1255-1278.
19. Marcos LA, Terashima A, Leguia G, et al. Fasciola hepatica infection in Peru: an emergent disease. Rev Gastroenterol Peru 2007; 27:389-396. This study reported approximately 1700 patients infected by F. hepatica from 1963 to 2007 in Peru, describing the epidemiology, clinical picture, diagnosis and treatment.
20. Parkinson M, O'Neill SM, Dalton JP. Endemic human fasciolosis in the Bolivian Altiplano. Epidemiol Infect 2007; 135:669-674. A meta-analysis of epidemiological surveys from 38 communities in the Bolivian Altiplano shows incidences of up to 67% of infected population, and prevalence is age related with the highest infection rate in children aged 8-11 years.
21. Marcos L, Maco V, Florencio L, et al. High prevalence rates of human fascioliasis in Peru: an emerging disease. Rev Per Enf Infec Trop 2005; 3:8-13.
22. Marcos LA, Romani L, Florencio L, et al. Hyperendemic and mesoendemic areas of Fasciola hepatica infection close to Lima city: an emergent disease? Rev Gastroenterol Peru 2007; 27:21-26.
23. Marcos LA, Maco V, Terashima A, et al. Hyperendemicity of human fascioliasis in the Mantaro valley: risk factors of Fasciola hepatica infection. Rev Gastroenterol Peru 2004; 24:158-164.
24. Marcos LA, Maco V, Terashima A, et al. Fascioliasis in relatives of patients with Fasciola hepatica infection in Peru. Rev Inst Med Trop Sao Paulo 2005; 47:219-222.
25. Maeda T, Yamada H, Akao N, et al. Unusual radiological findings of Fasciola hepatica infection with huge cystic and multilocular lesions. Intern Med 2008; 47:449-452.
26. Marcos LA, Maco V, Terashima A, et al. Clinical characteristics of Fasciola hepatica chronic infection in children. Rev Gastroenterol Peru 2002; 22:228-233.
27. Marcos LA, Maco V, Castillo M, et al. Report of cases of fascioliasis in the Specialized Children Health Institute in Peru (1988-2003). Rev Gastroenterol Peru 2005; 25:198-205.
28. Rana SS, Bhasin DK, Nanda M, Singh K. Parasitic infestations of the biliary tract. Curr Gastroenterol Rep 2007; 9:156-164. Good review of biliary parasite infection and radiologic imaging.
29. Aroonroch R, Worawichawong S, Nitiyanant P, et al. Hepatic fascioliasis due to Fasciola hepatica: a two-case report. J Med Assoc Thai 2006; 89:1770-1774.
30. Umac H, Erkek AB, Ayaslioglu E, et al. Pruritus and intermittent jaundice as clinical clues for Fasciola hepatica infestation. Liver Int 2006; 26:752-753.
31. El-Shazly AM, Soliman M, Gabr A, et al. Clinico-epidemiological study of human fascioliasis in an endemic focus in Dakahlia Governorate. J Egypt Soc Parasitol 2001; 31:725-736.
32. Bulbuloglu E, Yuksel M, Bakaris S, et al. Diagnosis of Fasciola hepatica cases in an operating room. Trop Doct 2007; 37:50-52.
33. Fullerton JK, Vitale M, Vitale GC. Therapeutic endoscopic retrograde cholangiopancreatography for the treatment of Fasciola hepatica presenting as biliary obstruction. Surg Innov 2006; 13:179-182.
34. Valero MA, Navarro M, Garcia-Bodelon MA, et al. High risk of bacterobilia in advanced experimental chronic fasciolosis. Acta Trop 2006; 100:17-23.
35. Valero M, Santana M, Hernandez J, Mas-Coma S. Risk of gallstone disease in advanced chronic phase of fascioliasis: an experimental study in a rat model. J Infect Dis 2003; 188:787-793.
36. Rondelaud D, Dreyfuss G, Vignoles P. Clinical and biological abnormalities in patients after fascioliasis treatment. Med Mal Infect 2006; 36:466-468.
37. Blancas G, Terashima A, Maguina C, et al. Human fascioliasis and gastrointestinal involvement: study of 277 patients in Cayetano Heredia National Hospital. 1970-2002. Rev Gastroenterol Peru 2004; 24:143-157.
38. Turhan O, Korkmaz M, Saba R, et al. Seroepidemiology of fascioliasis in the Antalya region and uselessness of eosinophil count as a surrogate marker and portable ultrasonography for epidemiological surveillance. Infez Med 2006; 14:208-212.
39. Almendras-Jaramillo M, Rivera-Medina J, Seijas-Mogrovejo J, Almendras-Jaramillo K. Hepatic fascioliasis in children: uncommon clinical manifestations. Arq Gastroenterol 1997; 34:241-247.
40. Heredia D, Bordas JM, Mondelo F, Rodes J. Gallbladder fascioliasis in a patient with liver cirrhosis. Med Clin (Barc) 1984; 82:768-770.
41. Sanchez-Sosa S, Rojas-Ortega S, Reed-San Roman G, Torres-Santana MA. Massive hepatobiliary fascioliasis. Rev Gastroenterol Mex 2000; 65:179-183.
42. Stack CM, Donnelly S, Lowther J, et al. The major secreted cathepsin L1 protease of the liver fluke, Fasciola hepatica: A leu-12 to pro-12 replacement in the nonconserved C-terminal region of the prosegment prevents complete enzyme autoactivation and allows definition of the molecular events in pro-segment removal. J Biol Chem 2007; 282:16532-16543. This study provides a molecular insight into the regulation of cathepsin L1, a major immunogenic cysteine proteinase released by F. hepatica.
43. Gironès N, Valero MA, García-Bodelón MA, et al. Immune suppression in advanced chronic fascioliasis: an experimental study in a rat model. J Infect Dis 2007; 195:1504-1512. This study shows that chronic fascioliasis may increase the risk for other infections in an animal model.
44. Espinoza JR, Timoteo O, Herrera-Velit P. Fas2-ELISA in the detection of human infection by Fasciola hepatica. J Helminthol 2005; 79:235-240.
45. Espinoza JR, Maco V, Marcos L, et al. Evaluation of Fas2-ELISA for the serological detection of Fasciola hepatica infection in humans. Am J Trop Med Hyg 2007; 76:977-982. This study validates the Fas2-ELISA for human diagnosis of fascioliasis. It was evaluated with hundreds of infected children in three different cities in Peru.
46. Cosme A, Ojeda E, Cilla G, et al. Fasciola hepatica study of a series of 37 patients. Gastroenterol Hepatol 2001; 24:375-380.
47. Kabaalioglu A, Cubuk M, Senol U, et al. Fascioliasis: US, CT, and MRI findings with new observations. Abdom Imaging 2000; 25:400-404.
48. Aksoy DY, Kerimoglu U, Oto A, et al. Fasciola hepatica infection: clinical and computerized tomographic findings of ten patients. Turk J Gastroenterol 2006; 17:40-45.
49. Orlent H, Selleslag D, Vandecasteele S, et al. Clinical challenges and images in GI. Fasciola hepatica infection and Von Hippel-Lindau disease type 1 with pancreatic and renal involvement. Gastroenterology 2007; 132:467-468.
50. Lumbreras H, Cantella R, Burga R. A rapid sedimentation procedure to investigate Fasciola hepatica eggs in stools, its evaluation and use in field. Rev Med Peru 1962; 31:167-174.
51. Talaie H, Emami H, Yadegarinia D, et al. Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients. Clin Exp Pharmacol Physiol 2004; 31:777-782.
52. El-Tantawy WH, Salem HF, Mohammed Safwat NA. Effect of fascioliasis on the pharmacokinetic parameters of triclabendazole in human subjects. Pharm World Sci 2007; 29:190. This study explains triclabendazole's properties, effectiveness and safety in humans.
53. Park GM. Genetic comparison of liver flukes, Clonorchis sinensis and Opisthorchis viverrini, based on rDNA and mtDNA gene sequences. Parasitol Res 2007; 100:351-357. This study suggests that Clonorchis and Opisthorchis are virtually identical despite belonging to entirely different genera and coming from different geographical areas.
54. Honjo S, Srivatanakul P, Sriplung H, et al. Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, Northeast Thailand. Int J Cancer 2005; 117:854-860.
55. Laha H, Pinlaor P, Mulvenna J, et al. Gene discovery for the carcinogenic human liver fluke, Opisthorchis viverrini. BMC Genomics 2007; 8:189.
56. Lim MK, Ju YH, Franceschi S, et al. Clonorchis sinensis infection and increasing risk of cholangiocarcinoma in the Republic of Korea. Am J Trop Med Hyg 2006; 75:93-96.
57. Tan SK, Qiu XQ, Yu HP, et al. Evaluation of the risk of clonorchiasis inducing primary hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 2008; 16:114-116.
58. Watthanakulpanich D, Waikagul J, Anantaphruti MT, Dekumyoy P. Evaluation of Bithynia funiculata snail antigens by ELISA: serodiagnosis of human opisthorchiasis. Southeast Asian J Trop Med Public Health 1997; 28:593-598.
59. Nagano I, Pei F, Wu Z, et al. Molecular expression of a cysteine proteinase of Clonorchis sinensis and its application to an enzyme-linked immunosorbent assay for immunodiagnosis of clonorchiasis. Clin Diagn Lab Immunol 2004; 11:411-416.
60. Zhao QP, Moon SU, Lee HW, et al. Evaluation of Clonorchis sinensis recombinant 7-kilodalton antigen for serodiagnosis of clonorchiasis. Clin Diagn Lab Immunol 2004; 11:814-817.
61. Duenngai K, Sithithaworn P, Rudrappa UK, et al. Improvement of PCR for detection of Opisthorchis viverrini DNA in human stool samples. J Clin Microbiol 2008; 46:366-368.
62. Choi MS, Choi D, Choi MH, et al. Correlation between sonographic findings and infection intensity in clonorchiasis. Am J Trop Med Hyg 2005; 73:1139-1144.
63. Ruangsittichai J, Viyanant V, Vichasri-Grams S, et al. Opisthorchis viverrini: identification of a glycine-tyrosine rich eggshell protein and its potential as a diagnostic tool for human opisthorchiasis. Int J Parasitol 2006; 36:1329-1339.
64. Keiser J, Utzinger J. Food-borne trematodiasis: current chemotherapy and advances with artemisinins and synthetic trioxolanes. Trends Parasitol 2007; 23:555-562.
65. Keiser J, Utzinger J. Artemisinins and synthetic trioxolanes in the treatment of helminth infections. Curr Opin Infect Dis 2007; 20:605-612. This is an excellent review of current and future prospects for therapy of trematodes.
66. Keiser J, Xiao SH, Dong Y, et al. Clonorchicidal properties of the synthetic trioxolane OZ78. J Parasitol 2007; 93:1208-1213.
67. Keiser J, Utzinger J, Xiao SH, et al. Opisthorchis viverrini: efficacy and tegumental alterations following administration of tribendimidine in vivo and in vitro. Parasitol Res 2008; 102:771-776.